Honolulu, HI — November 10, 2025 — Leads & Copy — CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) announced that three abstracts have been selected for poster presentation at the 2025 SNO Annual Meeting, scheduled for November 19-23, 2025, in Honolulu, HI.
The poster presentations include:
Title: Activity of Berubicin against Pediatric Diffuse Midline Glioma (DMG) cells: Preliminary data and future possibilities
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Abstract Code: EXTH-133
Date and Time: Friday, November 21, 2025 at 11:45 am – 1:05 pm HST
Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III
Title: TPI 287, which in combination with Bevacizumab (BEV) has shown activity in patients with glioblastoma (GBM) after prior therapy, will be evaluated in a Phase 2 trial as well as in other CNS diseases
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Abstract Code: CTNI-70
Date and Time: Saturday, November 22, 2025 at 11:45 am – 1:05 pm HST
Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III
Title: Primary results of the randomized clinical trial of Berubicin vs Lomustine in patients with glioblastoma after failure of primary therapy: Data analysis and future possibilities
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Abstract Code: CTNI-74
Date and Time: Saturday, November 22, 2025 at 11:30 am – 12:45 pm HST
Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III
CNS Pharmaceuticals is focused on developing treatments for cancers affecting the brain and central nervous system. Their pipeline includes drug candidates like TPI 287, an abeotaxane which stabilizes microtubules and inhibits cell division, leading to apoptosis and cell death. Clinical data suggests TPI 287 can cross the blood-brain barrier and treat CNS tumors. It has been tested in over 350 patients in clinical trials, both as a monotherapy and with bevacizumab, for conditions including recurrent glioblastoma, neuroblastoma, medulloblastoma, advanced malignancies, pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. It has shown an excellent safety profile and high tolerability.
For further details about the event, please visit the meeting website.
Jenene Thomas, JTC Team, LLC, 908.824.0775, CNSP@jtcir.com
Source: CNS Pharmaceuticals, Inc.
